WallStreetZenWallStreetZen

NYSE: TAK
Takeda Pharmaceutical Co Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TAK stock forecasts and price targets.

Forecast return on equity

Is TAK forecast to generate an efficient return?

Company
729.27%
Industry
286.15%
Market
228.88%
TAK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TAK forecast to generate an efficient return on assets?

Company
359.37%
Industry
157.64%
TAK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TAK earnings per share forecast

What is TAK's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$134.50+189,342.82%
Avg 2 year Forecast
$198.80+279,894.93%
Avg 3 year Forecast
$215.18+302,968.17%
TAK's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

TAK revenue forecast

What is TAK's revenue in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$4.6T+15,360.9%
Avg 2 year Forecast
$4.6T+15,452.14%
Avg 3 year Forecast
$4.7T+15,690.29%
TAK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TAK earnings growth forecast

How is TAK forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
1,380.65%
Industry
365.63%
Market
42.81%
TAK's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
TAK's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
TAK's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

TAK revenue growth forecast

How is TAK forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
443.07%
Industry
132.79%
Market
25.69%
TAK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TAK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TAK vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
TAK$14.28N/AN/A
HLN$9.53N/AN/A
ZTS$120.41$170.75+41.81%Strong Buy
TEVA$28.41$26.00-8.48%Strong Buy
NBIX$154.22$176.15+14.22%Strong Buy
View Top Pharmaceutical Stocks

Takeda Pharmaceutical Co Stock Forecast FAQ

What is TAK's earnings growth forecast for 2026-2028?

(NYSE: TAK) Takeda Pharmaceutical Co's forecast annual earnings growth rate of 1,380.65% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 365.63%, and it is also forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Takeda Pharmaceutical Co's earnings in 2025 is $217,722,185.On average, 18 Wall Street analysts forecast TAK's earnings for 2026 to be $213,994,591,648, with the lowest TAK earnings forecast at $151,239,111,004, and the highest TAK earnings forecast at $326,589,611,942. On average, 18 Wall Street analysts forecast TAK's earnings for 2027 to be $316,282,251,280, with the lowest TAK earnings forecast at $210,487,422,531, and the highest TAK earnings forecast at $427,172,530,280.

In 2028, TAK is forecast to generate $342,345,780,803 in earnings, with the lowest earnings forecast at $212,046,588,624 and the highest earnings forecast at $502,780,948,881.

If you're new to stock investing, here's how to buy Takeda Pharmaceutical Co stock.

What is TAK's revenue growth forecast for 2026-2028?

(NYSE: TAK) Takeda Pharmaceutical Co's forecast annual revenue growth rate of 443.07% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.69%.

Takeda Pharmaceutical Co's revenue in 2025 is $29,078,367,346.On average, 18 Wall Street analysts forecast TAK's revenue for 2026 to be $7,267,543,626,221,550, with the lowest TAK revenue forecast at $6,936,729,946,956,180, and the highest TAK revenue forecast at $7,814,763,195,227,100. On average, 18 Wall Street analysts forecast TAK's revenue for 2027 to be $7,310,433,421,660,572, with the lowest TAK revenue forecast at $6,779,254,171,581,360, and the highest TAK revenue forecast at $7,906,642,625,696,850.

In 2028, TAK is forecast to generate $7,422,376,774,167,621 in revenue, with the lowest revenue forecast at $6,604,627,569,185,520 and the highest revenue forecast at $8,232,396,970,089,600.

What is TAK's forecast return on assets (ROA) for 2026-2028?

(NYSE: TAK) forecast ROA is 359.37%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 157.64%.

What is TAK's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: TAK) Takeda Pharmaceutical Co's current Earnings Per Share (EPS) is $0.07. On average, analysts forecast that TAK's EPS will be $134.50 for 2026, with the lowest EPS forecast at $95.06, and the highest EPS forecast at $205.28. On average, analysts forecast that TAK's EPS will be $198.80 for 2027, with the lowest EPS forecast at $132.30, and the highest EPS forecast at $268.50. In 2028, TAK's EPS is forecast to hit $215.18 (min: $133.28, max: $316.02).

What is TAK's forecast return on equity (ROE) for 2026-2028?

(NYSE: TAK) forecast ROE is 729.27%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.